Walker, B.D., and Yu, X.G.: Unravelling the mechanisms of durable control of HIV-1. Nat. Rev. Immunol. 2013, 13:487–498.
13-34 The destruction of immune function as a result of HIV infection leads to increased susceptibility to opportunistic infection and eventually to death.
Kedes, D.H., Operskalski, E., Busch, M., Kohn, R., Flood, J., and Ganem, D.R.: The seroepidemiology of human herpesvirus 8 (Kaposi’s sarcoma associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat. Med. 1996, 2:918–924.
Miller, R.: HIV-associated respiratory diseases. Lancet 1996, 348:307–312.
Zhong, W.D., Wang, H., Herndier, B., and Ganem, D.R.: Restricted expression of Kaposi sarcoma associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proc. Natl Acad. Sci. USA 1996, 93:6641–6646.
13-35 Drugs that block HIV replication lead to a rapid decrease in titer of infectious virus and an increase in CD4 T cells.
Allers, K., Hütter, G., Hofmann, J., Loddenkemper, C., Rieger, K., Thiel, E., and Schneider, T.: Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood 2011, 117:2791–2799.
Barouch, D.H., and Deeks, S.G.: Immunologic strategies for HIV-1 remission and eradication. Science 2014, 345:169–174. Boyd, M., and Reiss, P.: The long-term consequences of antiretroviral therapy: a review. J. HIV Ther. 2006, 11:26–35. Cammack, N.: The potential for HIV fusion inhibition. Curr. Opin. Infect. Dis. 2001, 14:13–16.
Carcelain, G., Debre, P., and Autran, B.: Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy. Curr. Opin. Immunol. 2001, 13:483–488.
Farber, J.M., and Berger, E.A.: HIV’s response to a CCR5 inhibitor: I’d rather tighten than switch! Proc. Natl Acad. Sci. USA 2002, 99:1749–1751.
Ho, D.D.: Perspectives series: host/pathogen interactions. Dynamics of HIV-1 replication in vivo. J. Clin. Invest. 1997, 99:2565–2567.
Kordelas, L.,Verheyen, J., and Esser, S.: Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N. Engl. J. Med. 2014, 371:880–882.
Lundgren, J.D., and Mocroft, A.: The impact of antiretroviral therapy on AIDS and survival. J. HIV Ther. 2006, 11:36–38.